Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares

Bo Jesper Hansen sells 8 million shares

Bo Jesper Hansen has sold 8,000,000 of the shares he holds in Swedish Orphan Biovitrum AB (publ) (Sobi(TM)). He now owns 893,846 shares in Sobi.

On 26 February 2016 Sobi announced that Chairman Bo Jesper Hansen had informed Sobi's nomination committee that he will not stand for re-election at the 2016 Annual General Meeting of shareholders which will be held 24 May 2016. Håkan Björklund, former Nycomed CEO and Lundbeck Chairman, has been nominated as the new Chairman of the Board.


About Sobi(TM)

Sobi(TM) is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 380 M) and about 700 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com .

For more information please contact

Media relationsInvestor relations
Oskar Bosson, Head of CommunicationsJörgen Winroth, Vice President, Head of Investor Relations
+46 70 410 71 80+1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com

The information set out in this press release is announced in accordance with the Swedish Securities Market Act. The information was submitted for publication on 4 May 2016 at 08:00 CET.

024e_BJH sells shares

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire